Advertisement

Novel anti-cancer agents: design, synthesis, biological activity, molecular docking, and MD simulations of 2, 3, 4, 5-tetrahydro-1H-pyrido-[4,3-b]indole derivatives

  • Yu Feng
  • Xingxing Teng
  • Jinhua Gu
  • Bangwei Yu
  • Yan Luo
  • Lianbao Ye
Original Research
  • 71 Downloads

Abstract

In the previous research, our group designed and synthesized 2,3,4,5-tetrahydro-1H-pyrido-[4,3-b] indoles, which showed high anti-tumor activity. In this study, a series of novel 2,3,4,5-tetrahydro-1H-pyrido-[4,3-b] indole derivatives were designed by introducing an alkyl or aralkyl and a sulfonyl group, which are considered as the pharmacophores of some antitumor drugs based on the combination principles, and synthesized. The antiproliferative activity of all the target compounds were evaluated against Hela, A549, HepG2, and MCF-7 cell lines using the MTT assay in vitro. The results were represented by IC50 values. All compounds showed moderate to excellent antiproliferative activity with IC50 values between 0 μM and 100 μM against cancer cells. The proliferations of Hela, A549, HepG2, and MCF-7 cell lines were inhibited in a dose-dependent manner, and the cytolytic activity was markedly inhibited at the same time. The IC50 values of intermediate 3 inhibited against Hela, A549, HepG2, and MCF-7 cell lines were 52.75, 50.30, 60.31, and 54.39 μM, respectively, which were higher than the new compounds that we expected. The compounds 4a4d bearing sulfonyl, substituted by electron donating group, showed moderate to significant antiproliferative activity, in which compound 4c was the best with the IC50 values of 13.71, 9.42, 15.06, and 14.77 μM, and these results suggested that the introduction of sulfonyl could increase the antiproliferative activity of 2,3,4,5-tetrahydro-1H-pyrido-[4,3-b]indole. Compounds 4e4g bearing alkyl, phenyl, and arylated alkyl produced good antiproliferative activity and the IC50 value of 4g was lower than 30 μM. The target compounds were more potent against A549 compared to the other three cell lines. Molecular docking studies revealed the binding orientations of all the synthesized compounds in the active site of c-Met. Moreover, molecular dynamics simulations have been performed to evaluate the binding stabilities between the synthesized compounds and their receptors.

Keywords

2,3,4,5-Tetrahydro-1H-pyrido-[4,3-b]indole derivatives Design and synthesis Biological activities Molecular docking Molecular dynamics simulations 

Notes

Acknowledgements

The work was supported by the Special Innovation Project of Guangdong Education Department (Natural Science) (2017KTSCX107), Guangdong Natural Science Foundation (2015A03031356), Science and Technology Planning Project of Guangdong Province (2017ZC0199), Guangdong Provincial Applied Scientific and Technological Project (2015B020234009), National Scientific and Technological Project of Traditional Chinese Medicine Industry (201507004), Guangdong Pharmaceutical University’ School Powered by Innovation Foundation of China (2016KZDXM039), and Guangdong special training fund for university students’ scientific and technological innovation (51328004). The authors are grateful to Mr. Tan and Sun Yet-Sen University for molecular docking experiment.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

44_2018_2271_MOESM1_ESM.docx (1.1 mb)
Supplementary Information

References

  1. Bellacosa A, Yen T, Beeharry N, Smith M (2013) Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer. US Patent 2013-0303588, filled 15 Mar 2013, issued 6 Jan 2015Google Scholar
  2. Bhat M, Siddiqui N, Khan S (2006) Synthesis of novel thioureido derivatives of sulfonamides and thiosemicarbazido derivatives of coumarin as potential anticonvulsant and analgesic agents. Indian J Pharm Sci 68:120CrossRefGoogle Scholar
  3. Chandak N, Ceruso M, Supuran CT, Sharma PK (2016) Novel sulfonamide bearing scaffolds as selective inhibitors of tumor associated carbonic anhydrase isoforms IX and XII. Bioorg Med Chem 24:2882–2886CrossRefGoogle Scholar
  4. Dang YY, Li XC, Zhang QW, Li SP, Wang YT (2010) Preparative isolation and purification of six volatile compounds from essential oil of Curcuma wenyujin using high-performance centrifugal partition chromatography. J Sep Sci 33:1658–1664CrossRefGoogle Scholar
  5. Desai NC, Satodiya HM, Rajpara KM, Joshi VV, Vaghani HV (2014) ChemInform abstract: microwave assisted synthesis of new coumarin based 3-cyanopyridine scaffolds bearing sulfonamide group having antimicrobial activity. ChemInform 45:904–914Google Scholar
  6. Farahi M, Karami B, Tanuraghaj HM (2015) ChemInform abstract: efficient synthesis of a new class of sulfonamide-substituted coumarins. Tetrahedron Lett 56:1833–1836CrossRefGoogle Scholar
  7. He L, He F, Bi H, Li J, Zeng S, Luo HB, Huang M (2010) Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations. Bioorg Med Chem Lett 20:6008–6012CrossRefGoogle Scholar
  8. Hofmeister V, Schrama D, Becker JC (2008) Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 57:1–17CrossRefGoogle Scholar
  9. Hou JQ, Chen SB, Tan JH, Luo HB, Li D, Gu LQ, Huang ZS (2012) New insights from molecular dynamic simulation studies of the multiple binding modes of a ligand with G-quadruplex DNA. J Comput Aided Mol Des 26:1355–1368CrossRefGoogle Scholar
  10. Huang YY, Li Z, Cai YH, Feng LJ, Wu Y (2013) The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study. J Chem Inf Model 53:3044CrossRefGoogle Scholar
  11. Johnson DH (2000) Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and The Eastern Cooperative Oncology Group experience. Chest 117:133S–137SCrossRefGoogle Scholar
  12. Kovác M, Sabatié A, Floch L (2001) Synthesis of coumarin sulfonamides and sulfonylurea. Arkivoc 6:100–108Google Scholar
  13. Kircheis R, Wightman L, Kursa M, Ostermann E, Wagner E (2002) Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. Gene Ther 9:731–735CrossRefGoogle Scholar
  14. Lee TC, Su TL, Chon TC (2014) Method of treating cancer using combination of a bifunctional alkylating agent and DNA repair inhibitors. US Patent 8772284, filled 27 Oct 2010, issued 8 July 2014Google Scholar
  15. Luo X, Xiu N, Cheng L, Huang D (2001) Synthesis of coumarin dyes containing N -alkylsulfonamide groups. Dyes Pigm 51:153–159CrossRefGoogle Scholar
  16. Pirali T, Faccio V, Mossetti R, Grolla AA, Di Micco S, Bifulco G, Genazzani AA, Tron GC (2010) Synthesis, molecular docking and biological evaluation as HDAC inhibitors of cyclopeptide mimetics by a tandem three-component reaction and intramolecular [3+2] cycloaddition. Mol Divers 14:109–121CrossRefGoogle Scholar
  17. Thaisrivongs S, Tomich PK, Watenpaugh KD, Chong KT, Howe WJ, Yang CP, Strohbach JW, Turner SR, McGrath JP, Bohanon MJ (1994) Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors. J Med Chem 37:3200–3204CrossRefGoogle Scholar
  18. Tian Y, Shen Y, Zhang X, Ye L, Li Z, Liu Z, Zhang J, Wu S (2014) Design some new type I c-met inhibitors based on molecular docking and topomer CoMFA research. Mol Inform 33:536CrossRefGoogle Scholar
  19. Ye L, Tian Y, Li Z, Zhang J, Wu S (2012) Design and synthesis of some novel 2,3,4,5-tetra hydro -1H-pyrido [4,3-b]indoles as potential c-Met inhibitors. Helv Chim Acta 95:320–326CrossRefGoogle Scholar
  20. Ye L, Wu J, Yang J, Chen W, Luo L, Zhang Y (2016) Biological activity, molecular docking studies and molecular dynamics simulations of 2,3,4,5-tetrahydro-1H-pyrido[4,3-b] indoles as c-Met inhibitors. Lat Am J Pharm 35:416–420Google Scholar
  21. Ye L, Wu J, Chen W, Feng Y, Shen Z (2017) Novel anti-cancer agents based on germacrone: design, synthesis, biological activity, docking studies and MD simulations. RSC Adv 7:3760–3767CrossRefGoogle Scholar
  22. Ye L, Wu J, Yang J, Chen W, Luo Y, Zhang Y (2015) Design, synthesis and molecular docking analysis of some novel 7-[(quinolin-6-yl) methyl] purines as potential c-Met inhibitors. Med Chem Res 24:3327–3333CrossRefGoogle Scholar
  23. Yuan H, Zhuang J, Hu S, Li H, Xu J, Hu Y, Xiong X, Chen Y, Lu T (2014) Molecular modeling of exquisitely selective c-Met inhibitors through 3D-QSAR and molecular dynamics simulations. J Chem Inf Model 54:2544CrossRefGoogle Scholar
  24. Yan M, Wang H, Wang Q, Zhang Z, Zhang C (2016) Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor Tivantinib. Phys Chem Chem Phys 18:10367–10374CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Yu Feng
    • 1
  • Xingxing Teng
    • 1
  • Jinhua Gu
    • 1
  • Bangwei Yu
    • 2
  • Yan Luo
    • 1
  • Lianbao Ye
    • 1
    • 3
  1. 1.School of PharmacyGuangdong Pharmaceutical UniversityGuangzhouChina
  2. 2.Institute of Traditional Chinese MedicineGuangdong Pharmaceutical UniversityGuangzhouChina
  3. 3.Key Laboratory of New Drug Discovery and Evaluation of Ordinary Universities of Guangdong Province, Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems, Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems and Guangdong Province Engineering Technology Center for Molecular Probes & Biomedical ImagingGuangdong Pharmaceutical UniversityGuangdongChina

Personalised recommendations